第一线第三代EGFR氨酸激酶抑制剂单疗法用于EGFR突变的高级非小细胞肺癌:系统性审查和网络元分析.
Wei Du1,2, Anlin Li1,2, Bijing Xiao1,2
1State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center For Cancer Sun Yat-sen University Cancer Center Guangzhou China.
MedComm
|November 10, 2025
概括
第三代EGFR技术技能改善了先进EGFR突变NSCLC的结果. 这个贝叶斯网络元分析比较了它们的疗效和安全性,指导非小细胞肺癌患者的个性化治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 第三代表皮生长因子受体 (EGFR) 氨酸激酶抑制剂 (TKI) 代表了治疗先进的EGFR突变非小细胞肺癌 (NSCLC) 的重大进展.
- 目前缺乏对各种第三代EGFR TKIs的疗效和安全性简介的直接比较,这阻碍了最佳治疗选择.
研究的目的:
- 使用贝叶斯网络元分析进行第三代EGFR TKIs的首次对比比较.
- 评估和比较不同第三代EGFRTKIs在先进EGFR突变NSCLC中的疗效 (无进展生存率,客观响应率,内控制) 和安全性 (与治疗相关的不良事件).
主要方法:
- 对来自七项随机对照试验的数据进行了贝叶斯网络元分析,其中共有3012名患者.
- 疗效终点包括无进展生存 (PFS),客观反应率 (ORR) 和内控制.
- 通过比较不同第三代EGFRTKIs中严重治疗相关不良事件 (TRAE) 的发生率来评估安全性.
主要成果:
- 与第一代TKIs相比,所有第三代EGFRTKIs都显示出更高的无进展生存率 (PFS),第三代TKIs本身没有显著差异.
- 弗蒙尔蒂尼布显示了最高的PFS (HR,0.82),而阿莫尔蒂尼布提供了最好的内控制 (HR,0.74).
- 奥西默蒂尼布和拉泽蒂尼布比第一代TKI提供了整体生存益处. 与风险最高的befotertinib相比,furmonertinib,aumolertinib和osimertinib的严重TRAE较低 (RR,3.96).相比之下,befotertinib具有较低的严重TRAE,其风险最高.
结论:
- 这一贝叶斯网络元分析提供了对第三代EGFRTKI对先进的EGFR突变NSCLC的比较有效性和安全性的关键头对头见解.
- 这些发现支持根据患者特异性因素,如中枢神经系统转移或特定突变亚型的存在,对第三代EGFR TKIs进行个性化选择.
- 弗蒙尔蒂尼布,奥莫尔蒂尼布和奥西默蒂尼布似乎在严重的TRAE方面提供了有利的安全概况.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
9.2K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.6K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
428
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
428
